Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.35 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.35 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6783179 | 0.94 | KDM4E (0.40) | KDM4EMAPTTHRBELANEHTT | |
| SCHEMBL6621580 | 0.94 | NPC1 (0.42) | KDM4EMAPTTHRBELANEHTT | |
| SCHEMBL31517514 | 0.88 | USP2 (0.37) | KDM4EMAPTTHRBELANEHTT | |
| SCHEMBL10255933 | 0.88 | KDM4E (0.41) | KDM4EMAPTTHRBHTTNR1H2 | |
| SCHEMBL31517346 | 0.85 | KDM4E (0.35) | KDM4EMAPTTHRBELANEHTT | |
| SCHEMBL31517302 | 0.82 | KCNJ6 (0.35) | KDM4EMAPTTHRBELANENR1H2 | |
| SCHEMBL17045555 | 0.79 | PIK3CA (0.42) | KDM4EMAPTTHRBHTTGPR119 | |
| SCHEMBL4138174 | 0.79 | NPC1 (0.40) | CYP3A4GAACYP2C19NPC1LMNA | |
| SCHEMBL174902 | 0.77 | ALDH1A1 (0.43) | KDM4EELANECYP3A4CYP2C19MEN1 | |
| SCHEMBL13896431 | 0.77 | NPC1 (0.43) | MAPTHTTGAAKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025104236-A1 | PYRAZOLE COMPOUNDS AS CULLIN RING UBIQUITIN LIGASE COMPOUNDS | PROXYGEN GMBH (AT) | 2025-05-22 | — | — | WO | disclosed |
| WO-2025040546-A1 | PYRAZOLE COMPOUNDS AS CULLIN RING UBIQUITIN LIGASE COMPOUNDS | PROXYGEN GMBH (AT) | 2025-02-27 | — | — | WO | disclosed |
| US-20240270747-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| WO-2024131937-A1 | COMPOUND SERVING AS EIF4E INHIBITOR AND USE THEREOF | 南京圣和药业股份有限公司 | 2024-06-27 | — | — | WO | disclosed |
| CN-118239963-A | Compounds as eIF4E inhibitors and uses thereof | 南京圣和药业股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-112778311-B | Nitrogen-containing fused ring derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-06-04 | — | — | CN | disclosed |
| WO-2023203174-A1 | HETEROCYCLIC CULLIN RING UBIQUITIN LIGASE COMPOUNDS AND USES THEREOF | PROXYGEN GMBH (AT) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023203174-A1 | HETEROCYCLIC CULLIN RING UBIQUITIN LIGASE COMPOUNDS AND USES THEREOF | PROXYGEN GMBH (AT) | 2023-10-26 | — | — | WO | disclosed |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20080139561-A1 | e.g. 6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino) nicotinonitrile; tropomyosin-related kinases (Trk's) inhibitor; anticarcinogenic agent; hormone related cancer, leukemia; antiinflammatory agent; arthritis, restenosis; autoimmune diseases | ASTRAZENECA AB (SE) | 2008-06-12 | — | — | US | disclosed |
| EP-1853602-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006087538-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | WO | disclosed |
| US-20040116497-A1 | Chromane derivatives, process for their preparation and their use as antitumor agents | PHARMACIA ITALIA SPA (IT) | 2004-06-17 | — | — | US | disclosed |
| US-20040019046-A1 | Phenylacetamido-pyrazole derivatives and their use as antitumor agents | PHARMACIA ITALIA SPA (IT) | 2004-01-29 | — | — | US | disclosed |
| EP-1379524-A2 | CHROMANE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | Pharmacia Italia S.p.A. (IT) | 2004-01-14 | — | — | EP | disclosed |
| EP-1345909-A1 | PHENYLACETAMIDO-PYRAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | Pharmacia Italia S.p.A. (IT) | 2003-09-24 | — | — | EP | disclosed |
| US-6455559-B1 | Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents | PHARMACIA ITALIA S.P.A. (IT) | 2002-09-24 | — | — | US | disclosed |
| WO-2002070515-A2 | CHROMANE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA SPA (IT) | 2002-09-12 | — | — | WO | disclosed |
| WO-2002048114-A1 | PHENYLACETAMIDO- PYRAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA S.P.A. (IT) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139561-A1 | e.g. 6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino) nicotinonitrile; tropomyosin-related kinases (Trk's) inhibitor; anticarcinogenic agent; hormone related cancer, leukemia; antiinflammatory agent; arthritis, restenosis; autoimmune diseases | CNKSR1, LTK, MUSK | KDM4E 2477/4885MAPT 3902/4885THRB 167/4885 |
| US-20240270747-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | KDM4E 1352/4885MAPT 2050/4885THRB 1079/4885 |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | KDM4E 1352/4885MAPT 2050/4885THRB 1079/4885 |
| US-20040019046-A1 | Phenylacetamido-pyrazole derivatives and their use as antitumor agents | DCK, CCNK, CDK2 | KDM4E 2436/4885MAPT 2178/4885THRB 2956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.